Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31152623 | 0.98 | GPR84 (0.53) | GPR84FFAR1ZDHHC7ABCB1TSHR | |
| SCHEMBL27637191 | 0.98 | GPR84 (0.53) | GPR84FFAR1ZDHHC7ABCB1TSHR | |
| SCHEMBL17760822 | 0.98 | GPR84 (0.53) | GPR84FFAR1ZDHHC7ABCB1TSHR | |
| SCHEMBL2527545 | 0.88 | ALDH1A1 (0.41) | GPR84FFAR1ZDHHC7CA1CA2 | |
| SCHEMBL27704801 | 0.85 | ALDH1A1 (0.35) | GPR84FFAR1ZDHHC7 | |
| SCHEMBL27614024 | 0.84 | GPR84 (0.36) | GPR84FFAR1ZDHHC7 | |
| SCHEMBL28156113 | 0.84 | GPR84 (0.36) | GPR84FFAR1ZDHHC7 | |
| SCHEMBL28290657 | 0.84 | GPR84 (0.36) | GPR84FFAR1ZDHHC7 | |
| SCHEMBL3691540 | 0.84 | GPR84 (0.36) | GPR84FFAR1ZDHHC7 | |
| SCHEMBL503230 | 0.83 | ALDH1A1 (0.37) | GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686503-B2 | SPLITITNG FROM SOLID SUPPORT; METHYLATION | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-02-03 | — | — | US | disclosed |
| US-20010041345-A1 | Methods for the synthesis of highly substituted 2,4-dioxopiperidine libraries | CHAI WENYING (US) | 2001-11-15 | — | — | US | disclosed |
| US-6288235-B1 | MULTISTAGE REACTION WITH AMIDATION, CLEAVAGE FROM RESIN SUPPORT AND METHYLATION THEN CONDENSATION OF METHYL ESTER TO GIVE 2,4-DIOXOPIPERIDINE COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041345-A1 | Methods for the synthesis of highly substituted 2,4-dioxopiperidine libraries | DHPS, DRD4, DRD2 | GPR84 2170/4885FFAR1 3248/4885ZDHHC7 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.